SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-181625
Filing Date
2022-06-24
Accepted
2022-06-24 17:03:59
Documents
12
Period of Report
2022-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d296399d8k.htm   iXBRL 8-K 37585
  Complete submission text file 0001193125-22-181625.txt   164686

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gthx-20220623.xsd EX-101.SCH 2879
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20220623_lab.xml EX-101.LAB 18759
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20220623_pre.xml EX-101.PRE 11726
6 EXTRACTED XBRL INSTANCE DOCUMENT d296399d8k_htm.xml XML 3472
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 221040846
SIC: 2834 Pharmaceutical Preparations